Research Tree provides access to ongoing research coverage, media content and regulatory news on Glaukos.
We currently have 0 research reports from 0
Demand for ImmunoINSIGHTS profiling service is high and today’s release of data from its collaboration with Cedars-Sinai Medical Center illustrates further evidence of the value-add ImmunoINSIGHTS may have to potential customers across disease areas. There are a number of findings discussed in the paper, but with relevance to ONC shares, it shows the importance of using autoantibody profiling over a longitudinal basis to better understand symptomatology, disease duration and effective therapeuti
Companies: Oncimmune Holdings Plc
Companies: Medica Group Plc
ANGLE announced its second pharma services contract with an undisclosed drug development company, using Parsortix firstly to develop two custom CTC assays to look at biomarkers of DNA damage repair, for which it will be paid c.$0.4m and, secondly, if successful, to use these validated assays for longitudinal analysis in a subsequent clinical trial planned to start in H2 2022. The revenue from the first phase of the contract is expected to be recognised over a 12-month period. ANGLE also confirme
Companies: ANGLE plc
EKF recently unveiled a strategy for driving growth in the business over the next few years. It will be led by a refreshed executive management team and board, building on renewed strength in the core business and opportunities in developing wider contract development and manufacturing activities. Accretive bolt-on acquisitions will also be considered, all funded by the current strong net cash position of the group. Overall, the ambition is to deliver sustainable double-digit EBITDA growth into
Companies: EKF Diagnostics Holdings plc
This morning Oncimmune drew attention to the pre-publication of new research demonstrating the usefulness of its SeroTagTM Infectious Diseases (ID) discovery assay. The assay, part of the company’s ImmunoINSIGHTS offering, has been used by the US-based Cedars-Sinai Medical Center (Los Angeles) as part of an important study to demonstrate a stronger autoantibody response amongst male healthcare workers previously exposed to COVID-19, than female counterparts (82.4% versus 17.6%). A better underst
Oncimmune has announced an autoantibody profiling contract with the prestigious DanaFarber Cancer Institute. The contract opens up ImmunoINSIGHTS autoantibody profiling service to a number of Dana-Farber led oncology studies. We estimate the contract win to have minimal initial financial value, but importantly it brings influence and provides a framework for future use amongst pharmaceutical sponsors. Consequently, we make no changes to our estimates (projected 66% CAGR FY’21-23 in ImmunoINSIGHT
This morning Oncimmune announced a new contract with the Dana-Farber Cancer Institute (Harvard Medical School affiliate based in Boston, US) whereby the latter will utilise Oncimmune’s proprietary SeroTagTM ‘biomarker discover engine’ to identify predictive patient responses to novel checkpoint inhibitor (CPI) based cancer therapies. As in the case of yesterday’s announcement (see our note Cutting edge COVID-19 research validates ImmunoINSIGHTS as a valuable research tool) this new deal further
Verici Dx’s new scalable commercial testing facility in Franklin, Tennessee has earned a CLIA Certification for Registration by CMS that provides a permit to begin clinical testing. This award is in line with the accelerated CLIA approval strategy announced in February. It is an important milestone that brings forward expectations of a CPT code to be awarded in Q1 2022 (vs. Q2 2022) and removes a key regulatory barrier that was required to facilitate the commercial launch in 2022 of its two flag
Companies: Verici Dx Plc
What a difference a year makes - 12 months ago, the focus, quite understandably, was on the course of the pandemic and the lifting of the Lockdown (1) measures. For investors, it was the sustainability of the rally in markets seen since March 2020. Today, while we are still thinking about the lifting of lockdown measures, we are also concerned about two “old favourites” from previous decades. Inflation and the parlous state of public finances. The BoE has said that although CPI inflation rose to
Companies: AEMC BVC BAG BRSD BWNG CBOX CEG CTG CLG CML CRPR DNK EML ESC FAR FA/ GPH INSE MTW MOTR MMAG NRR NESF NMCN NSF OTMP OBD SAVE SCS STVG SNX SYS TMG TGL VLS VOG WYN
Belluscura is a medical device company focused on developing lightweight and portable oxygen enrichment technology. The group has announced that it has signed its fourth distribution agreement and started manufacturing the X-PLO2R, putting it firmly on track to meet its target commercial launch in Q3. The fourth distribution agreement is with a US Service disabled veteran-owned small business that deals exclusively with the US federal government in areas of veterans affairs. This follows on from
Companies: Belluscura PLC
Exceptional trading conditions through the Chinese Lunar New Year in February have prompted a further positive trading update from ECO, indicating revenue and EBITDA for FY21 will be significantly ahead of estimates that have already been upgraded several times. Conditions have also remained buoyant in markets such as the US and Brazil, with other territories remaining in line. As a result, we upgrade our FY21 revenue forecasts by a further 11% to £101.7m which translates to an adj EBITDA upgrad
Companies: ECO Animal Health Group plc
Creo Medical has announced that its lead product, Speedboat RS2, has received CE Mark approval for microwave (MW) energy to add to the device’s previous approval for radiofrequency (RF) energy. This approval realises the full potential of the Speedboat RS2 for both endoscopic cutting and coagulation, which we see as a significant market advantage over current technologies. Creo’s platform remains on track for a soft launch later this year. We maintain our Buy recommendation.
Companies: Creo Medical Group Plc
Creo Medical is a medical device company that is developing an instrument and generator system to facilitate a broader range of therapeutic interventions to be performed through an endoscope. We believe these instruments offer significant advantages over the current technology and could have applications across a number of therapeutic specialties.
Creo Medical has announced its first commercial orders for its lead Speedboat device. We see this as a significant milestone for the company, particularly as the order was received from the US, the largest healthcare market globally. This development maintains the strong momentum Creo Medical has delivered since it listed in 2016 and supports our expectation that the company will report its maiden revenues in FY19E. We maintain our Buy recommendation.
Creo Medical has announced the initiation of phase II of its clinical education programme for its lead product, Speedboat, in the US. This is a significant step, seeing a recently trained US gastrointestinal (GI) endoscopist training three further US clinicians. While Creo itself can train a number of physicians per year, having its trained practitioners running training programmes themselves will create a cascade effect, multiplying the number of trained Speedboat users, and therefore customers